Welcome to our dedicated page for Aprea Therapeutics SEC filings (Ticker: APRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aprea Therapeutics, Inc. (Nasdaq: APRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Aprea files reports with the U.S. Securities and Exchange Commission as a Delaware corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol APRE.
Among the key documents available through EDGAR are Aprea’s Form 8-K current reports, which the company uses to furnish earnings press releases, clinical program updates, financing announcements, and changes to its corporate presentation slide decks. For example, recent 8-K filings reference quarterly financial results, clinical updates from the ACESOT-1051 WEE1 inhibitor trial and the ABOYA-119 ATR inhibitor trial, and the establishment of a recommended Phase 2 dose for ATRN-119. Other 8-Ks describe private placement financing and the extension of projected cash runway.
Investors can also use the filings feed to monitor how Aprea discusses its lead programs, APR-1051 and ATRN-119, in official documents, including descriptions of trial objectives, biomarker-defined patient populations, and risk factor language incorporated by reference in periodic reports. While this page focuses on real-time access to filings such as 8-Ks, users can also locate annual reports on Form 10-K, quarterly reports on Form 10-Q, and any registration statements or prospectus supplements that relate to equity offerings mentioned in company news.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical milestones, financial condition, and strategic shifts like pausing monotherapy enrollment to consider combination therapies. The platform also surfaces new filings as they are posted to EDGAR, allowing close tracking of Aprea’s regulatory and disclosure history over time.
Aprea Therapeutics, Inc. reported that it received a deficiency letter from Nasdaq because its common stock has closed below the required
The company has 180 calendar days, until
Aprea Therapeutics, Inc. filed a current report to note that it has updated its corporate presentation slide deck as of January 9, 2026. The refreshed investor presentation is included as Exhibit 99.1 and is incorporated by reference, meaning it is treated as part of the official disclosure record. The filing does not describe the specific changes to the presentation, only that a new January 2026 version is now available.
Aprea Therapeutics, Inc. is registering 5,503,556 shares of common stock for potential resale by investors from a December 2025 private placement and related warrants. The shares consist of 26,459 already issued shares, 2,596,564 shares underlying pre-funded warrants, 2,623,023 shares underlying common warrants, and 257,510 warrant shares issued to Maxim Group LLC as compensation. Aprea will not receive proceeds from any resale, but may receive cash if warrants are exercised at $1.04 or $0.001 per share, which it plans to use for clinical trials, working capital and general corporate purposes. The registered securities represent about 79% of the 6,993,838 shares outstanding as of December 10, 2025, creating potential selling pressure on the stock. Aprea is a clinical-stage oncology company developing synthetic lethality therapies, including WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119, both in early-stage clinical development.
Aprea Therapeutics, Inc. reported that a director purchased 21,459 shares of common stock in a private placement on December 10, 2025 at a price of $1.165 per share and received accompanying common warrants to purchase up to 21,459 additional shares at an exercise price of $1.04.
After the transaction, the report shows 256,155 shares held directly, 602 shares held by a spouse and 21,459 common warrants. The warrants are immediately exercisable but cannot be used if exercise would push the holder above 4.99% beneficial ownership of common stock or 9.99% of the issuer’s total voting power, and they expire five years after the earlier of a registration of the underlying shares or the date those shares become eligible for resale under Rule 144 on a cashless basis.
Aprea Therapeutics, Inc.
As part of the same private placement, he also received common warrants to purchase up to 5,000 additional shares of common stock at an exercise price of $1.04 per share. The warrants are immediately exercisable but contain beneficial ownership limits that generally cap holdings at 4.99% of outstanding common stock or 9.99% of combined voting power. The warrants expire on the fifth anniversary of the earlier of the effectiveness of a registration statement for the underlying shares or the date those shares become eligible for sale under Rule 144, assuming cashless exercise.
Aprea Therapeutics, Inc. reported that its President and CEO, who also serves as a director, participated in a private placement that closed on December 10, 2025. The executive acquired pre-funded warrants to purchase 21,459 shares of common stock at a purchase price of $1.165 per pre-funded warrant, and received accompanying common warrants to purchase up to an additional 21,459 shares.
The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per share, and the common warrants are immediately exercisable at an exercise price of $1.04 per share, in each case subject to a beneficial ownership cap of 4.99% of outstanding common stock or 9.99% of total voting power. Following these transactions, the executive beneficially owns 345,620 common shares directly, plus additional shares held indirectly through a daughter and son, as well as the newly issued pre-funded and common warrants.
Aprea Therapeutics, Inc. filed a Form S-8 to register an additional 219,242 shares of its common stock, par value $0.001 per share, for issuance under the Aprea Therapeutics, Inc. 2019 Equity Incentive Plan. These shares are the same class of securities previously registered for the same plan on earlier Form S-8 registration statements.
The company is using the streamlined procedure under General Instruction E of Form S-8, incorporating by reference its prior S-8 filings that relate to the 2019 plan. The filing is signed on behalf of the company by President and Chief Executive Officer Oren Gilad, Ph.D., and other executive officers and directors, and includes standard exhibits such as the equity plan document, corporate charter and bylaws, legal opinion, consents, and filing fee table.
Aprea Therapeutics (APRE) filed its Q3 2025 10‑Q, reporting a net loss of $2,972,410 and cash and cash equivalents of $13,718,052. Operating expenses declined to $3,119,236 from $4,451,637 a year ago as both R&D and G&A trended lower. Interest income was $150,669.
The company stated that its September 30, 2025 cash balance will not fund operations for at least twelve months from issuance of the financial statements, indicating substantial doubt about continuing as a going concern. To bolster liquidity, Aprea raised approximately $0.8 million net during the nine months via its at‑the‑market program, issuing 468,567 shares. For the nine months, net loss was $10,143,939.
Program updates included setting the recommended Phase 2 dose of ATRN‑119 at 1,100 mg once daily and a strategic pause in further monotherapy enrollment while exploring combination studies. Common shares outstanding were 6,310,673 as of November 11, 2025.
Aprea Therapeutics, Inc. furnished a press release announcing financial results for the three and nine months ended September 30, 2025, and provided an operations update. The release is attached as Exhibit 99.1.
The company also filed an updated corporate presentation as Exhibit 99.2. Per General Instruction B.2, the Item 2.02 information, including Exhibit 99.1, is furnished and not deemed filed under Section 18, nor incorporated by reference unless expressly stated.
Aprea Therapeutics (APRE) reported an other event, stating it issued a press release with a clinical update from the ACESOT-1051 trial that shows early signals of activity for its WEE1 kinase inhibitor, APR-1051.
The press release is attached as Exhibit 99.1 and incorporated by reference. This notice informs the market of new clinical observations; detailed results and context are contained in the attached press release.
FAQ
What is the current stock price of Aprea Therapeutics (APRE)?
What is the market cap of Aprea Therapeutics (APRE)?
